Several studies indicated an increase of the MCP–1 in breast cancer and melanoma [22,23] and others showed that in patients with gastric cancer, serum level of MCP–1 decreased according tothe progression of the disease, probably reflecting its local consumption [24]. This evidence concerns the gene CCL2 and melanoma.